SCHEMBL3868476

SCHEMBL3868476

COc1ccc(-n2nc(C(=O)CCCO[N+](=O)[O-])cc2-c2ccc(S(C)(=O)=O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 13/20 1.00
PTGS1 P23219 5/20 1.00
CHRNA7 P36544 2/20 0.59
RPA1 P27694 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
MALT1 Q9UDY8 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867579 0.91 PTGS2 (0.83) PTGS2PTGS1CHRNA7CA9HDAC3
SCHEMBL3865167 0.90 PTGS2 (0.82) PTGS2PTGS1CHRNA7
SCHEMBL3864455 0.90 PTGS2 (0.82) PTGS2PTGS1CHRNA7RPA1MALT1
SCHEMBL3862668 0.90 PTGS2 (0.82) PTGS2PTGS1CHRNA7CA9HDAC3
SCHEMBL3865468 0.90 PTGS2 (0.81) PTGS2PTGS1CHRNA7CA9HDAC3
SCHEMBL3864248 0.88 PTGS2 (0.78) PTGS2PTGS1CHRNA7RPA1CA1
SCHEMBL3864401 0.88 PTGS2 (0.78) PTGS2PTGS1CHRNA7
SCHEMBL3865581 0.88 PTGS2 (0.78) PTGS2PTGS1CHRNA7RPA1CA1
SCHEMBL5677910 0.86 PTGS2 (0.75) PTGS2PTGS1CHRNA7
SCHEMBL3862779 0.81 PTGS2 (0.68) PTGS2PTGS1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US claimed
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1534683-A4 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-08-24 EP disclosed
EP-1534683-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-01 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002409-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.